Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma (CUE)
:CUE
CUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $2.26
Previous CloseN/A
Volume91.78K
Average Volume (3M)159.95K
Market Cap
$47.02M
Enterprise Value$67.34M
Total Cash (Recent Filing)-$6.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 13, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding61,819,100
10 Day Avg. Volume129,879
30 Day Avg. Volume159,952
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.54
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.07
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$2.00Price Target Upside163.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cue Biopharma News
PremiumCompany Announcements
Cue Biopharma’s Strategic Focus and Financial Outlook
PremiumCompany Announcements
Cue Biopharma Appoints Pasha Sarraf to Board
PremiumCompany Announcements
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
---
Bulls Say, Bears Say
Bulls Say
Partnership OpportunitiesThe potential for an upcoming partnership for CUE-501 and a research collaboration with Ono Pharmaceuticals provides non-dilutive capital.
Product DevelopmentCue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.
Strategic FocusCue Biopharma focuses all resources on developing assets targeting autoimmune disease, seen as a strategic move that could position the company as an interesting turnaround story.
Bears Say
Clinical Development ChallengesThe presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.
Financial ConstraintsThe cash runway is expected to last until mid-2025, suggesting potential financial constraints if additional partnerships or funding are not secured.
Oncology Program DeprioritizationThe company recently deprioritized the oncology programs and will refocus efforts in autoimmune disease indications.
---
Ownership Overview
0.52% Insiders
4.22% Mutual Funds
10.62% Other Institutional Investors
81.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma’s price range in the past 12 months?
Cue Biopharma lowest stock price was $0.45 and its highest was $2.26 in the past 12 months.
What is Cue Biopharma’s market cap?
Cue Biopharma’s market cap is $47.02M.
When is Cue Biopharma’s upcoming earnings report date?
Cue Biopharma’s upcoming earnings report date is May 13, 2025 which is in 38 days.
How were Cue Biopharma’s earnings last quarter?
Cue Biopharma released its earnings results on Mar 31, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.005.
Is Cue Biopharma overvalued?
According to Wall Street analysts Cue Biopharma’s price is currently Undervalued.
Does Cue Biopharma pay dividends?
Cue Biopharma does not currently pay dividends.
What is Cue Biopharma’s EPS estimate?
Cue Biopharma’s EPS estimate is -0.09.
How many shares outstanding does Cue Biopharma have?
Cue Biopharma has 61,819,100 shares outstanding.
What happened to Cue Biopharma’s price movement after its last earnings report?
Cue Biopharma reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went down -17.582%.
Which hedge fund is a major shareholder of Cue Biopharma?
Currently, no hedge funds are holding shares in CUE
---
Cue Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (163.16% Upside)
$2.00 (163.16% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.06%
12-Months-Change
Fundamentals
Return on Equity
-149.03%
Trailing 12-Months
Asset Growth
-47.68%
Trailing 12-Months
Company Description
Cue Biopharma
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of biologics designed to selectively engage and modulate the human immune system to treat a broad range of cancers, chronic infectious diseases, and autoimmune disorders. The company's proprietary Immuno-STAT™ platform enables the selective modulation of disease-relevant T cells in the patient's body, offering a potentially transformative approach to immunotherapy.
---
CUE Stock 12 Month Forecast
Average Price Target
$2.00
▲(163.16% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Affimed
―
Adaptimmune Therapeutics
―
Corvus Pharmaceuticals
―
Best Analysts Covering CUE
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-32.96%
reiterated a buy rating 5 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -32.96% per trade.
---